Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Leukemia
Karube, K K; Enjuanes, A A; Dlouhy, I I; Jares, P P; Martin-Garcia, D D; Nadeu, F F; Ordóñez, G R GR; Rovira, J J; Clot, G G; Royo, C C; Navarro, A A; Gonzalez-Farre, B B; Vaghefi, A A; Castellano, G G; Rubio-Perez, C C; Tamborero, D D; Briones, J J; Salar, A A; Sancho, J M JM; Mercadal, S S; Gonzalez-Barca, E E; Escoda, L L; Miyoshi, H H; Ohshima, K K; Miyawaki, K K; Kato, K K; Akashi, K K; Mozos, A A; Colomo, L L; Alcoceba, M M; Valera, A A; Carrió, A A; Costa, D D; Lopez-Bigas, N N; Schmitz, R R; Staudt, L M LM; Salaverria, I I; López-Guillermo, A A; Campo, E E
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Haematologica
Scharenberg, Christian C; Giai, Valentina V; Pellagatti, Andrea A; Saft, Leonie L; Dimitriou, Marios M; Jansson, Monika M; Jädersten, Martin M; Grandien, Alf A; Douagi, Iyadh I; Neuberg, Donna S DS; LeBlanc, Katarina K; Boultwood, Jacqueline J; Karimi, Mohsen M; Jacobsen, Sten Eirik W SE; Woll, Petter S PS; Hellström-Lindberg, Eva E